Asthma - Acute Exacerbation and Emergency Management

Asthma Management Overview Asthma management follows a stepwise approach divided into two main strategies: quick-relief medications for acute symptoms and long-term controller medications for chronic disease control. This dual approach allows clinicians to address immediate airway obstruction while simultaneously reducing underlying inflammation and preventing future exacerbations. Quick-Relief (Rescue) Medications Short-acting beta-2 agonists (SABAs) are the first-line medications for acute symptom relief in asthma. The most common example is salbutamol (albuterol in the United States). How SABAs work: These medications stimulate beta-2 receptors on airway smooth muscle, causing rapid relaxation and bronchodilation—opening the airways within minutes. This makes them ideal for acute attacks when patients experience sudden shortness of breath. Delivery methods: In acute settings, SABAs can be delivered via metered-dose inhalers (MDIs) with a spacer or through nebulizers, which convert liquid medication into a fine mist for inhalation. In children, spacers may offer advantages over nebulizers for delivering SABAs, as they reduce oropharyngeal deposition and improve drug delivery to the lungs. Enhanced relief in moderate-to-severe attacks: Anticholinergic agents (ipratropium) can be added to SABAs to provide additional benefit. These medications work through a different mechanism—blocking acetylcholine-mediated airway constriction—and their combination with SABAs produces superior bronchodilation compared to either drug alone. Long-Term Controller Medications While rescue medications address acute symptoms, chronic asthma control requires ongoing anti-inflammatory therapy. Inhaled corticosteroids (ICS) are the cornerstone of asthma controller therapy. Why corticosteroids? Asthma is fundamentally an inflammatory airway disease. Corticosteroids suppress eosinophilic and T-cell-mediated inflammation, reduce mucus production, and prevent airway remodeling—addressing the root cause rather than just symptoms. ICS advantages: By inhaling the medication directly into the lungs, patients achieve high local anti-inflammatory effects while maintaining minimal systemic side effects (unlike oral corticosteroids). When ICS alone isn't enough: For patients whose asthma remains uncontrolled on ICS monotherapy, long-acting beta-2 agonists (LABAs) are added. This combination provides sustained bronchodilation while maintaining anti-inflammatory control. LABA+ICS combination therapy has become standard for step-up therapy. Alternative or additional options: Leukotriene receptor antagonists (like montelukast) can be used as add-on therapy. These block the inflammatory effects of leukotrienes—powerful mediators released during asthma attacks—making them useful in patients with exercise-induced or allergic asthma. Systemic Corticosteroids for Exacerbations During acute exacerbations, systemic corticosteroids (oral or intravenous) rapidly reduce airway inflammation when inhaled medications are insufficient. These are given acutely during moderate-to-severe exacerbations to control inflammation that develops over hours or days, not just minutes. The key distinction: SABAs provide rapid bronchodilation, but systemic corticosteroids address the underlying inflammation that causes the exacerbation. Management of Severe or Refractory Asthma A subset of patients—those with type 2-high severe asthma—fail to respond adequately to standard ICS/LABA therapy. Biologic agents have revolutionized treatment for these patients. Omalizumab targets IgE, reducing allergen-mediated airway inflammation in patients with atopic asthma. Other biologic agents target interleukin pathways (IL-4, IL-5, IL-13), directly suppressing T helper cell 2 (Th2) inflammatory responses that drive eosinophilic asthma. These biologics are expensive and reserved for patients with demonstrated severe asthma who remain uncontrolled despite optimized conventional therapy. Acute Asthma Exacerbation Management Acute exacerbations require a coordinated, stepwise approach in emergency settings. The severity of the exacerbation determines which additional therapies are needed beyond standard SABAs and corticosteroids. Initial Assessment and Oxygen Therapy The first step is assessing oxygenation. Supplemental oxygen is initiated when arterial oxygen saturation (SpO₂) falls below 92%. Humidified oxygen is preferred as it moistens airways and may provide mild symptom relief. This threshold of 92% is critical: below this level, tissue oxygen delivery becomes compromised, and supplemental oxygen becomes necessary. Short-Acting Beta-Agonist Administration SABAs are the immediate, first-line bronchodilator in acute exacerbations. Delivery can occur via: Metered-dose inhaler with spacer — more portable, faster administration Nebulizer — continuous aerosol delivery, useful when patient cooperation is limited The choice depends on severity and clinical setting. Magnesium Sulfate for Moderate-to-Severe Attacks For moderate-to-severe exacerbations unresponsive to initial SABA therapy, intravenous magnesium sulfate is added to standard treatment. Magnesium acts as a smooth muscle relaxant and has several benefits: Improves bronchodilation when combined with SABAs and corticosteroids Reduces hospital admissions in adults with acute asthma Works synergistically with SABAs through a different physiological mechanism This is important to understand: magnesium is not first-line (SABAs and corticosteroids are), but it's a proven adjunct in severe cases. Advanced Therapies in Severe Cases Intravenous salbutamol is not supported by evidence and is reserved only for extreme cases where other routes are impossible. Standard nebulized or inhaled delivery is always preferred. <extrainfo> Heliox and mechanical ventilation are considered last-resort measures. Heliox (helium-oxygen mixture) reduces airway resistance by decreasing gas density, potentially improving flow in severely obstructed airways. Mechanical ventilation becomes necessary only when patients develop severe hypoxemia unresponsive to all medical therapies—a rare scenario indicating life-threatening asthma status asthmaticus. </extrainfo> Emergency Department Management Acute Exacerbation Protocols Emergency departments manage acute exacerbations using a standardized protocol: SABAs — immediate bronchodilator relief Systemic corticosteroids — address underlying inflammation Supplemental oxygen — maintain SpO₂ ≥ 92% Magnesium sulfate — for severe cases unresponsive to initial therapy Non-invasive ventilation — if respiratory failure develops Ketamine — a sedative used during intubation in severe cases due to its bronchodilatory properties This stepwise escalation ensures that additional therapies are added only when previous interventions prove insufficient. Monitoring and Follow-Up Regular spirometry or peak-flow monitoring between exacerbations assesses whether the patient's asthma is controlled and guides medication adjustments. Declining spirometry or frequent peak-flow drops indicate inadequate control requiring therapy escalation. Written asthma action plans are crucial interventions. These individualized documents outline: When to use rescue vs. controller medications Warning signs of exacerbations When to seek emergency care Contact information for their clinician Patients with written action plans have significantly fewer emergency department visits, demonstrating that self-management education reduces acute exacerbations. Structured discharge planning and follow-up interventions are particularly effective in children with asthma, reducing repeat emergency visits through close outpatient monitoring and medication adherence support.